Evidence map›Paper›PMID 27464949›Full record

ArticleWorld journal of surgical oncology2016

Laparoscopic RFA with splenectomy for hepatocellular carcinoma.

Kunpeng Hu, Purun Lei, Zhicheng Yao, Chenhu Wang, Qingliang Wang, Shilei Xu, Zhiyong Xiong, He Huang, Ruiyun Xu, Meihai Deng and 1 more

Open access · goldAbstract read
In one paragraph

Article in World journal of surgical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Benefits of Splenectomy and Curative Treatments for Patients with Hepatocellular Carcinoma and Portal Hypertension: a Retrospective Study.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2019
    Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Kunpeng HuDepartment of General Surgery, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510000, China.
Purun LeiDepartment of Gastrointestinal Surgery, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510000, China.
Zhicheng YaoDepartment of General Surgery, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510000, China.
Chenhu WangDepartment of General Surgery, Affiliated Hospital of Jiangnan University, Wuxi, 214000, China.
Qingliang WangDepartment of General Surgery, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510000, China.
Shilei XuDepartment of General Surgery, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510000, China.
Zhiyong XiongDepartment of Hepatobiliary Surgery, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510000, China.
He HuangDepartment of General Surgery, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510000, China.
Ruiyun XuDepartment of Hepatobiliary Surgery, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510000, China.
Meihai DengDepartment of Hepatobiliary Surgery, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510000, China.
Bo LiuDepartment of General Surgery, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510000, China. liubojake@126.com.
Sun Yat-sen University · CNThird Affiliated Hospital of Sun Yat-sen University · CNWuxi Fourth People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe treatment of hepatocellular carcinoma (HCC) is complicated and challenging because of the frequent presence of cirrhosis. Therefore, we propose a novel surgical approach to minimize the invasiveness and risk in patients with HCC, hypersplenism, and esophagogastric varices.

methodsThis was a retrospective study carried out in 25 patients with HCC and hypersplenism and who underwent simultaneous laparoscopic-guided radio-frequency ablation and laparoscopic splenectomy with endoscopic variceal ligation. Tumor size was restricted to a single nodule of <3 cm. Characteristics of the patients (cirrhosis etiology, liver function, tumor size, spleen size), surgery (complications, blood loss, time of stay), and follow-up (recurrence and survival) were examined.

resultsMean operative time was 128 ± 18 min. Mean blood loss was 206 ± 57 mL. Length of stay was 7.0 ± 1.5 days. Mean total costs were 8064 USD. Cytopenia and thrombocytopenia recovered quickly after surgery. No procedure was converted to open surgery. Two patients showed worsening liver function after surgery, three patients showed worsening of ascites, and five patients suffered from portal vein thrombosis. The 1-year tumor-free survival was 78.8 %, and the 21-month tumor-free survival was 61.4 %. According to a literature review, these outcomes were comparable to those of simultaneous open hepatic resection and splenectomy.

conclusionsLaparoscopic-guided radio-frequency ablation with laparoscopic splenectomy and endoscopic variceal ligation could be an available technique for patients with HCC <3 cm, hypersplenism, and esophagogastric varices. This approach may help to minimize the surgical risks and results in a fast increase in platelet counts with an acceptable rate of complications.

Indexed as

AdultAgedBlood Loss, SurgicalCarcinoma, HepatocellularCatheter AblationDisease-Free SurvivalEsophageal and Gastric VaricesFemaleFollow-Up StudiesHumansHypersplenismLaparoscopyLength of StayLigationLiver CirrhosisLiver NeoplasmsAblationEndoscopic variceal ligationHepatocellular carcinomaHypersplenismLaparoscopySplenectomy

Identifiers

PMID27464949
PMCPMC4963946
OpenAlexW2493535877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.